FDA-Approved Drugs

Cardiology/Vascular Diseases
Edarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011

Dermatology/Plastic Surgery
Gralise (gabapentin); Abbott; For the treatment of postherpetic neuralgia, Approved February 2011 Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011 Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011

Endocrinology
Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011 Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011 Tradjenta (linagliptin); Boehringer Ingelheim; For the treatment of type II diabetes, Approved May 2011

Gastroenterology
Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011 Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011 Incivek (telaprevir); Vertex; For the treatment of genotype 1 chronic hepatitis C, Approved May 2011 Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011 Victrelis (boceprevir); Merck; For the treatment of chronic hepatitis C genotype 1, Approved May 2011

Immunology/Infectious Diseases Benlysta (belimumab). For the treatment of systemic juvenile idiopathic arthritis. Approved February 2011 Oncology . Approved May 2011 Victrelis (boceprevir). Approved March 2011 Daliresp (roflumilast). Approved January 2011 Obstetrics/Gynecology Makena (hydroxyprogesterone caproate injection). For the treatment of HIV-1. Approved February 2011 Edurant (rilpivirine). Abbott. Approved April 2011 Viibryd (vilazodone hydrochloride). Human Genome Sciences. Merck. ProStrakan. Genentech. Tibotec. For the treatment of postherpetic neuralgia. For the treatment of systemic lupus erythematosus. Approved January 2011 Gralise (gabapentin). For the treatment of genotype 1 chronic hepatitis C. Abbott. For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers. For the treatment of chronic obstructive pulmonary disease. For the treatment of breakthrough cancer pain in opioid-tolerant patients. Approved May 2011 Gralise (gabapentin). For the prevention of risk of preterm birth. For the treatment of restless legs syndrome. For the treatment of postherpetic neuralgia. Approved April 2011 Neurology Abstral (fentanyl sublingual tablets). For the treatment of chronic hepatitis C genotype 1. Horizon Pharma. Approved April 2011 Duexis (ibuprofen and famotidine). For the treatment of major depressive disorder. Clinical Data. Forest Pharmaceuticals. Approved February 2011 Incivek (telaprevir). Approved May 2011 Musculoskeletal Actemra (tocilizumab). Hologic. Vertex. GlaxoSmithKline. Approved February 2011 Horizant (gabapentin enacarbil).

For the treatment of advanced pancreatic neuroendocrine tumors. Approved April 2011 Yervoy (ipilimumab). Pfizer. Approved April 2011 Pediatrics/Neonatology Actemra (tocilizumab). Genentech. Approved March 2011 Zytiga (abiraterone acetate). Forest Pharmaceuticals. Bristol-Myers Squibb. Genentech. Approved May 2011 Sutent (sunitinib malate). For the treatment of thyroid cancer. Approved January 2011 Afinitor (everolimus). Clinical Data. Approved April 2011 Daliresp (roflumilast). Astra Zeneca. Approved May 2011 Sylatron (peginterferon alfa-2b). For the treatment of breakthrough cancer pain in opioid-tolerant patients. Centocor Ortho Biotech. For the treatment of systemic juvenile idiopathic arthritis. For the treatment of melanoma. For the treatment of chronic obstructive pulmonary disease. ProStrakan. For the treatment of thyroid cancer. Approved February 2011 Psychiatry/Psychology Viibryd (vilazodone hydrochloride). Approved April 2011 . For the treatment of prostate cancer. Novartis. Approved January 2011 Pulmonary/Respiratory Diseases Daliresp (roflumilast). Approved May 2011 Otolaryngology Vandetanib (vandetanib). For the treatment of major depressive disorder. For the treatment of systemic juvenile idiopathic arthritis. Merck. For the treatment of pancreatic neuroendocrine tumors. Approved February 2011 Rheumatology Actemra (tocilizumab). Astra Zeneca. Forest Pharmaceuticals. For the treatment of chronic obstructive pulmonary disease. For the treatment of metastatic melanoma. Approved April 2011 Vandetanib (vandetanib).Abstral (fentanyl sublingual tablets).

Approved December 2010 Prolia (denosumab). For the treatment of bacterial skin infections and bacterial pneumonia. For the treatment of hypertension. For the risk reduction of stroke and embolism due to atrial fibrillation. Approved March 2010 Endocrinology Fortesta (testosterone gel). Daiichi Sankyo.Duexis (ibuprofen and famotidine). For the treatment of acne vulgaris. Approved August 2010 Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide). For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers. For the treatment of postmenopausal women with osteoporosis at high risk for fracture. Approved December 2010 Pradaxa (dabigatran etexilate mesylate). Approved April 2011 2010 FDA approved drugs Cardiology/Vascular Diseases Amturnide (aliskiren + amlodipine + hydrochlorothiazide). Approved July 2010 Zyclara (imiquimod). Graceway. Cerexa. Novartis. For the treatment of hypertension. For the treatment of actinic keratoses of the face and scalp. For the treatment of hypogonadism. For the treatment of uncontrolled hypertension. For the treatment of type 2 diabetes mellitus. Boehringer Ingeleheim. Amgen. Approved January 2010 Gastroenterology . Horizon Pharma. Novartis. Stiefel. Approved June 2010 Victoza (liraglutide). November 2010 Veltin (clindamycin phosphate and tretinoin). Approved July 2010 Dermatology/Plastic Surgery Teflaro (ceftaroline fosamil). Approved October 2010 Tekamlo (aliskiren + amlodipine). Novo Nordisk. Endo Pharmaceuticals.

Approved April 2010 Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine). For the treatment of rheumatoid arthritis. November 2010 Zortress (everolimus). For the treatment of bacterial skin infections and bacterial pneumonia. oropharyngeal candidiasis. chemotherapy and radiotherapy induced nausea and vomiting. Approved January 2010 . Gilead Sciences. Johnson & Johnson. Approved February 2010 Egrifta (tesamorelin for injection). For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Approved November 2010 Menveo (meningitis vaccine).Herceptin (trastuzumab). Novartis. Shire. For the prevention of postoperative. For the treatment of arthritis in patients at risk for NSAID-associated ulcers. Strativa Pharmaceuticals. AstraZeneca. For the treatment of type 1 Gaucher disease. For the treatment of bacterial conjunctivitis. For the active immunization to prevent invasive meningococcal disease. Strativa Pharmaceuticals. Approved February 2010 Teflaro (ceftaroline fosamil). Approved July 2010 Hematology Vpriv (velaglucerase alfa for injection). Cerexa. For the prevention of organ rejection following kidney transplant. For the active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae. Approved May 2010 Zymaxid (gatifloxacin ophthalmic solution). For the treatment of exocrine pancreatic insufficiency. Approved May 2010 Musculoskeletal Actemra (tocilizumab). Allergan. Novartis. Approved October 2010 Pancreaze (pancrelipase). Approved March 2010 Immunology/Infectious Diseases Cayston (aztreonam for inhalation solution). Wyeth. Theratechnologies. For the treatment of gastric cancer. Genentech. Approved April of 2010 Vimovo (naproxen + esomeprazole). Genentech. Approved February 2010 Oravig (miconazole). Approved April 2010 Zuplenz (ondansetron oral soluble film).

Merz Pharmaceutical. Approved May 2010 Xifaxan (rifaximin). For the treatment of postmenopausal women with osteoporosis at high risk for fracture.Ampyra (dalfampridine). Approved June 2010 Jevtana (cabazitaxel). Approved November 2010 Xiaflex (collagenase clostridium histolyticum). For the treatment of benign prostatic hyperplasia. For the treatment of hormone refractory prostate cancer. Approved March 2010 Zortress (everolimus). For the prevention of organ rejection following kidney transplant. For the treatment of chronic gout (hyperuricemia). Approved June 2010 Provenge (sipuleucel-T). Approved April 2010 Xeomin (incobotulinumtoxinA). For the treatment of prostate cancer. Approved January 2010 . Allergan. Approved March 2010 Jalyn (dutasteride + tamsulosin). For the treatment of hyperammonemia. sanofi aventis. Approved June 2010 Vimovo (naproxen + esomeprazole). Approved February 2010 Nephrology/Urology Carbaglu (carglumic acid). For the treatment of arthritis in patients at risk for NSAID-associated ulcers. For the treatment of cervical dystonia and blepharospasm. Salix. Approved September 2010 Prolia (denosumab). For the treatment of relapsing multiple sclerosis. Approved September 2010 Krystexxa (pegloticase). Auxilium Pharmaceuticals. For the prevention of skeletal-related events in patients with bone metastases from solid tumors. For the improvement of walking in patients with multiple sclerosis. Acorda. For the improvement of walking in patients with multiple sclerosis. Approved July 2010 Xgeva (denosumab). Approved March 2010 Gilenya (fingolimod). For the treatment of upper limb spasticity. Savient Pharma. Recordati. Novartis. For the treatment of hepatic encephalopathy. Dendreon. AstraZeneca. Acorda. Approved January 2010 Botox (onabotulinumtoxinA). For the treatment of Dupuytren¶s contracture. Approved May 2010 Neurology Ampyra (dalfampridine). Novartis. Amgen. GlaxoSmithKline. Amgen.

Approved March 2010 Obstetrics/Gynecology ella (ulipristal acetate). For the treatment of postmenopausal women with osteoporosis at high risk for fracture. For the treatment of metastatic breast cancer. Approved March 2010 Botox (onabotulinumtoxinA). For the treatment of chronic migraine. Alkermes. For the treatment of chronic severe drooling in pediatrics with neurologic conditions. Approved March 2010 Kapvay (clonidine hydrochloride). Approved October 2010 Vpriv (velaglucerase alfa for injection). Approved March 2010 Sprix (ketorolac tromethamine). For the prevention of contraception. Avanir Pharmaceuticals. For the emergency prevention of contraception. Approved October 2010 Nuedexta (dextromethorphan hydrobromide and quinidine sulfate). Shionogi Pharma. Roxro Pharma. Approved June 2010 . Amgen. Approved October 2010 Silenor (doxepin). Approved March 2010 Cuvposa (glycopyrrolate). For the treatment of hepatic encephalopathy. Somaxon Pharma. For the treatment of insomnia. Approved November 2010 Natazia (estradiol valerate + dienogest). Approved October 2010 Butrans (buprenorphine) Transdermal System. Allergan. Shire. HRA Pharma. Purdue Pharma. Recordati. Alza. For the treatment of upper limb spasticity.Botox (onabotulinumtoxinA). Approved July 2010 Exalgo (hydromorphone hydrochloride) extended release. For the prevention of relapse to opioid dependence. Approved August 2010 Halaven (eribulin mesylate). Salix. For the treatment of moderate to severe pain. Approved May 2010 Prolia (denosumab). Approved March 2010 Xifaxan (rifaximin). Approved July 2010 Carbaglu (carglumic acid). Eisai. Bayer. For the treatment of attention deficit hyperactivity disorder. Allergan. Approved May 2010 Vivitrol (naltrexone for extended-release injectable suspension). For the treatment of type 1 Gaucher disease. For the treatment of hyperammonemia. moderate to severe chronic pain. Shionogi. For the management of moderate to severe pain. For the treatment of pseudobulbar affect.

For the treatment of acne vulgaris. Approved July 2010 Dulera (mometasone furoate + formoterol fumarate dihydrate). chemotherapy and radiotherapy induced nausea and vomiting. Shionogi Pharma. For the treatment of bacterial conjunctivitis. Approved May 2010 Otolaryngology Oravig (miconazole). For the treatment of asthma. Strativa Pharmaceuticals. For the treatment of metastatic breast cancer. Approved November 2010 Zuplenz (ondansetron oral soluble film). For the prevention of postoperative. Approved November 2010 Herceptin (trastuzumab). Approved November 2010 . Shionogi. Approved July 2010 Ophthalmology Zymaxid (gatifloxacin ophthalmic solution). For the treatment of gastric cancer. Merck. Eisai. Approved May 2010 Xgeva (denosumab). Allergan. Theratechnologies. For the treatment of chronic severe drooling in pediatrics with neurologic conditions. Approved October 2010 Veltin (clindamycin phosphate and tretinoin).Oncology Halaven (eribulin mesylate). Approved April 2010 Pediatrics/Neonatology Cuvposa (glycopyrrolate). Approved July 2010 Pharmacology/Toxicology Egrifta (tesamorelin for injection). Approved June 2010 Kapvay (clonidine hydrochloride). Amgen. For the prevention of skeletal-related events in patients with bone metastases from solid tumors. For the treatment of prostate cancer. Genentech. For the treatment of hormone refractory prostate cancer. oropharyngeal candidiasis. Strativa Pharmaceuticals. Approved October 2010 Jevtana (cabazitaxel). Dendreon. For the treatment of attention deficit hyperactivity disorder. Approved June 2010 Provenge (sipuleucel-T). For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Stiefel. sanofi aventis.

Approved April 2010 Trauma/Emergency Medicine Zuplenz (ondansetron oral soluble film). For the treatment of bacterial skin infections and bacterial pneumonia. AstraZeneca. Sunovion. chemotherapy and radiotherapy induced nausea and vomiting. For the treatment of major depressive disorder. Approved January 2010 Krystexxa (pegloticase). Genentech. Approved July 2010 Psychiatry/Psychology Latuda (lurasidone). November 2010 Rheumatology Actemra (tocilizumab). For the treatment of arthritis in patients at risk for NSAID-associated ulcers. Approved June 2010 Teflaro (ceftaroline fosamil). Approved July 2010 . Merck.Zuplenz (ondansetron oral soluble film). For the treatment of asthma. chemotherapy and radiotherapy induced nausea and vomiting. For the treatment of rheumatoid arthritis. Approved October 2010 Oleptro (trazodone hydrochloride). For the treatment of schizophrenia. Approved October 2010 Pulmonary/Respiratory Diseases Cayston (aztreonam for inhalation solution). Cerexa. Labopharm. Savient Pharma. For the treatment of chronic gout (hyperuricemia). For the prevention of postoperative. Gilead Sciences. Approved September 2010 Vimovo (naproxen + esomeprazole). Approved February 2010 Vivitrol (naltrexone for extended-release injectable suspension). Alkermes. Strativa Pharmaceuticals. For the prevention of postoperative. Approved February 2010 Dulera (mometasone furoate + formoterol fumarate dihydrate). For the prevention of relapse to opioid dependence. For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. Strativa Pharmaceuticals.